Inebilizumab is a monoclonal antibody medication used to treat neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that primarily affects the optic nerves and spinal cord.
Inebilizumab targets CD19-positive B cells, which play a role in the autoimmune process underlying NMOSD.
By depleting these B cells, it helps reduce inflammation and prevent relapses.
Brand name: Uplizna
Given as an intravenous infusion.
The usual regimen involves two initial infusions followed by maintenance dosing every six months.
Approved for adults with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive.
Clinical trials showed it significantly reduced the risk of NMOSD attacks compared to placebo, helping patients maintain neurological function and quality of life.
Side effects: Common side effects can include infusion reactions, increased risk of infections due to B cell depletion, and potential reactivation of hepatitis B in carriers.
In patients with acetylcholine receptor antibody positive or muscle specific positive generalized myasthenia gravis inbelizumab improved function and reduced severe disease severity.
Patients typically need regular monitoring for infections and other potential complications related to immune suppression.